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Deregulated signaling via the phosphatidylinositol 3-kinase (PI3K)
pathway is common in many types of cancer, but its clinicopathological
significance in endometrial cancer remains unclear. In the present
study, we examined the status of the PI3K signaling pathway,
especially in relation to PTEN and PIK3CA status, in endometrioid-
type endometrial cancer. The immunohistochemical analysis revealed
a high level of phosphorylated (p)-AKT expression, which is a
hallmark of activated PI3K signaling, in approximately 60% of
endometrial cancers. There was no correlation between p-AKT
expression and clinicopathological characteristics, such as International
Federation of Gynecology and Obstetrics stage, tumor grade, and
myometrial invasion. Unexpectedly, a high level of p-AKT expression
occurred independently of the presence of PTEN or PIK3CA mutations.
Furthermore, p-AKT expression did not correlate with the expression
of potential downstream targets, including p-mTOR and p-FOXO1/3a.
In turn, p-AKT expression was strongly associated with extracellular-
regulated kinase 1/2 expression (P = 0.0031), which is representative
of the activated RAS–MAP kinase pathway. Kaplan–Meier analysis
suggested that low p-AKT expression was associated with low rates
of relapse-free survival, although the difference was not statistically
significant, indicating that AKT activation does not confer worse
prognosis. The present study demonstrates the presence of complex
signaling pathways that might mask the conventional tumorigenic
PTEN–PI3K–AKT–mTOR pathway, and strongly suggests a close
association between the extracellular-regulated kinase and PI3K
pathways in this tumor type. (Cancer Sci 2007; 98: 1881–1888)
E ndometrial cancer is the second most common gynecologicalmalignancy in Japan, and its incidence in Japan has
increased dramatically over the last decade. Although prem-
alignant lesions of endometrial cancer have been well characterized,
the molecular pathways of endometrial carcinogenesis remain
unclear. Inactivation of the PTEN gene, mainly via gene mutation,
is the most common genetic abnormality detected in endometrioid-
type endometrial cancer.(1–3) PTEN is a tumor-suppressor
gene encoding a lipid phosphatase that dephosphorylates pho-
sphatidyl inositol 3,4,5-triphosphate (PI[3,4,5]P3), thus opposing
the action of phosphoinositide 3-kinase (PI3K).(4,5) PI(3,4,5)P3
is converted to PI(3,4)P2, which activates the proto-oncogene
AKT (also called PKB). Activation of AKT, which is caused by
its phosphorylation, antagonizes apoptotic pathways via activation
of mTOR or inactivation of the forkhead family, whereas
dephosphorylation of PI(3,4,5)P3 by PTEN induces activation
of the apoptotic pathway.(6–8) Thus, the fundamental in vivo role
of PTEN is to inhibit the PI3K–AKT pathway. Mutation of
PTEN can disable this inhibitory function, thus inducing the
antiapoptotic pathway, which is believed to be the key to
endometrial carcinogenesis. Other critical factors involved in
regulation of the PI3K–AKT pathway are mutations in genes
that encode components of PI3K. Recent studies have identified
non-random somatic mutations in the PIK3CA gene, which
encodes the p110α catalytic subunit of PI3K, in various
cancers.(9) Reported mutations have been of the missense
type and clustered within two regions of the helical (exon 9) and
kinase (exon 20) domains, and the mutant proteins have been
shown to display enhanced lipid-kinase activity. PIK3CA mutation
has recently been identified in 20–40% of endometrial cancers.(10–12)
Other prevalent genetic abnormalities in endometrial carcino-
genesis are mutations in the KRAS gene.(13,14) The extracellular-
regulated kinase (ERK)–mitogen-activated protein kinase (MAPK)
pathway is activated by mitogenic stimuli mediated by receptor-
type tyrosine kinases and G protein-coupled receptors, leading
to sequential phosphorylation of RAS, RAF, MEK, and ERK1/2.
Phosphorylated (p)-ERK1/2 translocates to the nucleus and
regulates a range of substrates that promote cell proliferation,
motility, differentiation, and survival.(15–17) A KRAS mutation can
lead to continuous stimulation of its downstream targets, result-
ing in ERK1/2 activation in the absence of mitogenic stimuli.
Thus, most of these prevalent genetic alterations observed in
endometrial cancer stimulate the PI3K–AKT and MAPK–ERK
pathways, and may play major roles in endometrial carcinogenesis
as well as disease progression. In a previous study, we examined
the status of the ERK–MAPK pathway in endometrial cancer,
and found that ERK1/2 activation was a significant prognostic
factor.(18) Unexpectedly, ERK1/2 activation frequently occurred
irrespective of KRAS status, and was associated with a favorable
prognosis. Thus, it appears that the widely recognized canonical
RAS–RAF–MEK–ERK1/2 signaling pathway does not contribute
to disease progression of endometrial carcinogenesis, at least
in the late stage.
Given these unexpected features of the ERK1/2 pathway, in
the present study, we assessed the status of the PI3K–AKT
pathway in endometrial cancer, especially in relation to PTEN
and PI3KCA mutation. We also examined whether the PI3K–
AKT pathway affects tumor behavior or is a prognostic factor,
attempted to identify downstream targets of AKT, and assessed
the relationship between the ERK–MAPK and PI3K–AKT
signaling pathways. We carried out these analyses using clinical
samples of endometrial cancer and found unexpected results,
raising questions about the roles of PTEN and PIK3CA mutation
in activating the PI3K–AKT pathway or the significance of such
signaling in the oncogenic potential of endometrial cancers.
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Materials and Methods
Patients and tissue samples. A total of 63 patients with
endometrioid-type endometrial cancer (mean age, 57.5 years;
range, 32–78 years) treated at the Department of Obstetrics and
Gynecology, Kanazawa University Hospital, from January 1995
to December 2002, were enrolled in the study. All patients
underwent a total abdominal or radical hysterectomy plus bilateral
salpingo-oophorectomy. Systemic retroperitoneal lymphadenectomy
was carried out in approximately 70% of the patients. Staging
was carried out for all patients using the International Federation of
Gynecology and Obstetrics (FIGO) surgical staging system: 46
tumors were classified as stage I (substages: Ia, 10 tumors; Ib,
28 tumors; and Ic, eight tumors); six tumors were classified as
stage II (substages: IIa, three tumors; and IIb, three tumors); nine
tumors were classified as stage III (substages: IIIa, three tumors;
and IIIc, six tumors); and two tumors were classified as stage IV.
Based on histological examination, 34 tumors were classified as
grade (G)1, 14 tumors were classified as G2, and 15 tumors
were classified as G3. Patients with deep myometrial invasion,
cervical involvement, and special histology underwent external
radiotherapy, whereas those with positive peritoneal cytology or
retroperitoneal lymph-node metastasis were treated with four to
six cycles of CAP chemotherapy (90 mg/m2 cisplatin; 50 mg/m2
doxorubicin; and 500 mg/m2 cyclophosphamide) or TJ chemotherapy
(180 mg/m2 paclitaxel; and carboplatin, according to Chatelut’s
formula [area under the curve (AUC) = 5 mg/mL/min]) as
postoperative adjuvant therapy. Patient treatment was followed
up with a gynecological examination, recording of laboratory
data, transvaginal and abdominopelvic ultrasonography, and a
radiological examination. Data from regular follow-up visits to
the outpatient department were stored in a database designed
specifically for endometrial carcinoma patients. A telephone
survey to update the status of all surviving patients was made in
August 2004. The exact date of disease recurrence was defined
as the date when the apparent tumors were detected by
ultrasonographic or radiological examinations.
Tumor samples were collected at the time of surgery, with written
informed consent and approval of the Ethics Committee of Kanazawa
University. Half of each tissue sample was examined histologically
by pathologists, and the remaining portion of each sample was
frozen at –80°C until DNA extraction for mutation analysis.
PTEN and PIK3CA mutation analysis. Of the 63 endometrial cancers,
45 were available for DNA sequencing, in which 38 cancers had
been evaluated previously for mutations in PTEN.(3,19) All exons
of the PTEN gene were amplified by polymerase chain reaction
(PCR) using primer sets described previously.(3) Exons 9 and 20
of the PIK3CA gene, which were known to be hot spots of gene
mutations, were also amplified by PCR using primer sets described
previously.(9) PCR products were purified using the Qiagen PCR
purification kit (Qiagen), and direct sequencing was carried out.
PCR products with suspected mutations were reamplified and
subsequently cloned into the pGEM-T Easy vector (Promega),
and sequencing was carried out using at least three clones.
Analysis of microsatellite instability. DNA samples from endometrial
cancers and normal areas of the endometrium were analyzed
using a panel of five microsatellite markers for the dinucleotide
repeat sequences D2S123, D2S147, D10S197, D13S175, and
D18S58, as described elsewhere.(20) Myometrial samples from
each patient served as controls. The PCR products of the micro-
satellite markers were analyzed using ABI GeneScan (Applied
Biosystems, Foster City, CA, USA). The samples were classified
as high-frequency microsatellite instability (MSI) (PCR
bands had shifted compared with those of the myometrial control
samples for two or more of the five loci), low-frequency MSI
(one locus), or microsatellite stable (no loci).(21)
Immunohistochemistry. Immunohistochemical analysis was carried
out using formalin-fixed, paraffin-embedded specimens from 63
endometrioid-type endometrial cancer tissues. Sections were
stained with rabbit monoclonal antibody to p-AKT (#3787) or
with rabbit polyclonal antibodies to p-mTOR (#2974) and
p-FOXO1(Thr24)/FOXO3a(Thr32) (#9464) (Cell Signaling
Technology, Beverly, MA, USA).
After the specimens were deparaffinized in xylene and graded
alcohols, epitope retrieval was carried out. The sections were
heated in a microwave oven at 700 W for 10 min in 1× antigen
retrieval solution (Biogenex, San Ramon, CA, USA). Then,
endogenous peroxidase was blocked by immersing the sections
in 0.3% H2O2–methanol for 30 min. After blocking with horse
serum, the (above-described) appropriate primary antibodies at
1 : 50 (for p-AKT and p-FOXO1/3a) or at 1 : 100 (for p-mTOR)
were diluted and applied for 16 h at 4°C. The reaction was vis-
ualized using the EnVision Detection Kit (Dako Cytomation,
Glostrup, Denmark) using diaminobenzidine tetrahydrochloride
as the enzyme substrate. All sections were counterstained with
GM hematoxylin stain solution (Muto Pure Chemicals, Tokyo,
Japan). For negative controls, the primary antibody was omitted.
For the absorption test, primary antibody against p-AKT was
incubated with two volumes of p-Akt blocking peptide (#1140;
Cell Signaling Technology) for 30 min prior to adding the entire
volume to the slide. The expression of p-Akt was scored into
four levels: no, weak, moderate, and strong. Stained sections were
evaluated blindly without prior knowledge of the clinico-
pathological parameters by two observers, who scored the
percentage of positive nuclei and cytoplasms within tumors. The
average staining score was registered, and there was no statistical
significance in the scoring between observers. For the survival
analysis, patients with no or weak expression were assigned
to the low-expression group, and those with moderate or strong
expression were assigned to the high-expression group.
Western blot analysis. Whole-cell lysates were prepared by
resuspending frozen cancer tissues in buffer containing 50 mM
Tris-HCl (pH 7.4), 1% Nonidet P40 (Fluka), and 1 mM ethylenedia-
minetetraacetic acid for 10 min at room temperature. The homogenate
was centrifuged at 12 000g for 5 min. The supernatant was
recovered, and its protein concentration was measured by Bradford
assay. Then, 30 μg of extract was electrophoresed on a sodium
dodecylsulfate–polyacrylamide gel with a gradient of 10–20%
(Readygels J, 161-J351; Bio-Rad, Hercules, CA, USA), and was
then transferred to a polyvinylidene difluoride membrane.
Membranes were blocked with TBS-T (150 mM NaCl, 20 mM
Tris-HCl [pH 7.5], and 0.1% Tween 20) containing 5% non-fat
dried milk, and were then incubated with specific primary
antibody against p-AKT (#4058; Cell Signaling Technology),
followed by incubation with horseradish peroxidase-linked antirabbit
IgG. Immunoreactive bands were visualized using the ECL detection
system (Amersham), according to the manufacturer’s instructions.
As an internal control for equal protein loading, actin expression
was examined simultaneously using a specific antibody (sc-1615;
Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Statistical analysis. Statistical analysis was carried out using
the statistical package StatView version 5.0 (Abacus Concepts,
Berkeley, CA, USA). We used the χ2-test for 2 × 2 tables to
compare the categorical data. Life tables were computed using
the Kaplan–Meier method, whereas the log-rank test was used
to assess statistical significance. Cox’s proportional hazards
regression model with a stepwise manner was used to analyze
the independent prognostic factors. A P-value < 0.05 was considered
to indicate statistical significance.
Results
Mutational analysis of PTEN and PI3KCA in endometrioid-type 
endometrial cancer. We first identified PTEN mutations in
endometrioid-type endometrial cancer. Of the 45 cancers
available for DNA sequencing, 18 cancers (40%) had mutations
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in the PTEN gene: point mutations in eight patients, and
frameshift mutations in 10 patients. Some of these data have
been reported previously.(3,19) The clinicopathological and molecular
features of patients with PTEN mutation are summarized in
Table 1. PTEN mutation was observed in 13 of the 25 (52%)
grade 1 cancers, 3 of the 11 (27.2%) grade 2 cancers, and two of
the nine (22.2%) grade 3 cancers; thus, lower-grade cancers
were more likely to have a PTEN mutation, but the differences
were not statistically significant. There were no significant
correlations between PTEN mutation and other clinicopathological
features (data not shown). As we reported previously,(3) PTEN mut-
ations, especially the frameshift mutations, were tightly associated
with MSI (Table 1), indicating that some of the PTEN mutations
are caused by mismatch repair deficiency.
We next identified PIK3CA mutations. A total of seven can-
cers (15.6%) had mutations in exons 9 or 20 of the PI3KCA
gene. All were missense mutations (Table 1). Five of them
(71%) were observed in grade 1 cancers, whereas one was grade
2 and one was grade 3. There were no significant correlations
between PIK3CA mutation and clinicopathological features
(data not shown). Unlike the PTEN gene, PIK3CA mutations
appeared to be independent of MSI status. Four cancers had
both PTEN and PIK3CA mutations. PI3KCA mutations were
more common in cancers with PTEN mutations (4 of 18, 22.2%)
compared to those without PTEN mutations (3 of 27, 11.1%).
Activation of AKT frequently occurs in endometrial cancer, but is 
independent of PTEN or PIK3CA status. Immunohistochemical analysis
was then carried out for the expression of p-AKT in endometrial
cancer. Expression of p-AKT was basically detected in the
cytoplasm but some samples had both cytoplasmic and nuclear
staining, especially in samples with strong expression (Fig. 1).
There were 13 patients with weak p-AKT expression, 27 with
moderate expression, and nine with strong expression. Thus, 36
of the 63 cancers (57.1%) had moderate or strong expression of
p-AKT. The expression of p-AKT was further confirmed by
western blot analysis in some patients whose protein extracts
were available, and there was a tight correlation between the
results of immunohistochemistry and western blot analysis (Fig. 2).
We then assessed the correlation between p-AKT expression and
clinicopathological characteristics (Table 2). There was no
correlation between p-AKT expression and any of the following:
patient age, FIGO stage, lymph-node metastasis, depth of myometrial
invasion, pathological grade, menopause, or body mass index
(BMI). We also assessed the correlation between PTEN or
PIK3CA status and p-AKT expression (Tables 1,3). Unexpectedly,
there was no statistically significant correlation between PTEN
or PIK3CA mutations and p-AKT expression (Table 3). We paid
special attention to cancers with the coexistence of PTEN and
PIK3CA mutations, because this may induce p-AKT expression
more efficiently. However, of the four cancers that had both
PTEN and PIK3CA mutations, one had strong, two had moderate,
and one had weak expression of p-AKT (Table 1), indicating
that coexistence of the mutations did not necessarily lead to
enhanced expression of p-AKT in endometrial cancer. Finally,
we assessed the involvement of KRAS mutation in p-AKT
expression, because it is known that RAS activates PI3K both
directly and indirectly in some cancer types.(20) We found a total
of 10 cancers with KRAS mutations in codon 12 or codon 13 of
exon 1,(18) but no significant correlation was observed between
KRAS mutation and p-AKT expression (P = 0.15, data not shown).
Activation of AKT does not lead to phosphorylation of mTOR  or members 
of the forkhead family, but is strongly associated with ERK1/2 activation 
in endometrial cancer. The known representative downstream targets
of AKT are mTOR and the FOXO family, two members of
Table 1. Clinicopathological and molecular features of 21 endometrial cancers with mutations in the PTEN or PIK3CA genes
Patient no. Age (years) FIGO stage Grade MSI PTEN mutation PIK3CA mutation p-AKT expression†
1 70 Ib 1 H Ex5; G389T, R130L Ex20; A3140T, H1047L +
2 58 Ib 3 L Ex20; A3140G, H1047R −
3 71 Ib 1 H Ex8; G871A, E291K Ex20; A3140T, H1047L +
Ex8; 863 del A, fs (stop at 868)
4 52 Ic 2 H Ex8; 946 ins G, fs (stop at 970) −
Ex8; 987 del TAAA, fs (stop at 1024)
5 41 Ic 2 H Ex5; A446G, Q149R ++
Ex8; 863 del A, fs (stop at 868)
6 44 Ia 1 H Ex8; A938G, K313R ++
Ex8; 963 del A, fs (stop at 1027)
7 47 Ib 1 H Ex8; 963 del A, fs (stop at 1027) ±
8 58 Ib 1 H Ex8; 923 ins A, fs (stop at 931) −
9 62 Ib 2 MSS Ex20; A3140G, H1047R −
10 54 Ib 1 MSS Ex5; C388G, R130G +
11 64 Ic 2 MSS Ex1; A76C, T26P −
12 43 Ia 1 H Ex8; A815G, H272R +
Ex8; 950 del TACT, fs (stop at 955)
13 67 Ia 1 MSS Ex5; G389A, R130Q Ex9; C1636G, Q546E ++
14 33 Ia 1 H Ex5; 336 del AAGTG, fs (stop at 340) +
15 68 Ia 1 H Ex8; 956 del CTTT (stop at 1024) +
16 49 Ia 1 MSS Ex5; C388T, R130stop −
17 55 Ic 3 L Ex5; C462A, F154L ++
18 59 Ib 1 H Ex20; A3036G, E1002E ++
19 63 Ib 1 MSS Ex5; G389A, R130Q Ex20; A3062G, Y1021C ±
Ex5; C424T, R142W
20 55 Ib 1 ND Ex5; C388T, R130stop ±
21 53 Ic 3 ND Ex5; 493 ins A, fs (stop at 499) +
†– negative, +/– weak, + moderate, ++ strong. Some of the data have been reported previously.(3,19) EX, exon; FIGO, International Federation of 
Gynecology and Obstetrics; H, high-frequency microsatellite instability; L, low-frequency microsatellite instability; MSI, microsatellite instability; 
MSS, microsatellite stable; ND, not done; p-AKT, phosphorylated AKT.
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which (FOXO1 and FOXO3a) play key roles in cell-cycle
regulation and apoptosis.(22) Therefore, we immunohistochemically
examined the expression of p-mTOR and p-FOXO1/3a (Fig. 3),
and assessed their correlations with the expression of p-AKT.
We observed p-mTOR expression in 58 of the 63 patients (92%):
seven (11%) with weak expression, 39 (62%) with moderate
expression, and 12 (19%) with strong expression. We observed
p-FOXO1/3a expression in 51 of the 63 patients (81%): 16 (25%)
with weak expression, 27 (43%) with moderate expression, and
eight (13%) with strong expression. There was no significant
correlation between the expression of p-AKT and the expression of
p-mTOR or p-FOXO1/3a (Tables 4,5), indicating that AKT activation
does not always trigger the canonical downstream signaling pathway
in endometrial cancer. We further examined the relationship
between PTEN and PIK3A mutations and mTOR or p-FOXO1/3a
expression, but no significant correlation was observed (PTEN
mutation vs p-mTOR, P = 0.074; PTEN or PIK3CA mutation vs p-
mTOR, P = 0.098; PTEN mutation vs p-FOXO1/3a, P = 0.77; PTEN
or PIK3CA mutation vs p-FOXO1/3a, P = 0.51).
In a previous study, we observed the expression of p-ERK1/2
in 41 out of 63 endometrial cancers (65.1%).(18) Consequently,
in the present study, we assessed the correlation between p-AKT
and p-ERK1/2 expression in endometrial cancer, and found a
strong association between them (P = 0.0031) (Table 6; Fig. 3).
Fig. 1. Representative results of phosphorylated
(p)-AKT immunohistochemistry in endometrial
cancer specimens. (a) A sample with negative
staining. (b) A sample with moderate expression.
(c,e) Cases with strong expression, showing both
nuclear and cytoplasmic expression. (d,f) Absorption
test using p-AKT blocking peptide in (d) case C
and (f) case E. The staining completely disappeared
with the addition of blocking peptide. (Original
magnification ×200. Scale bars = 100 μm.)
Fig. 2. Representative results of western blot
analysis in endometrial cancer specimens. Ten
patients with strong (++) or no/weak (–)
phosphorylated (p)-AKT expression assessed by
immunohistochemistry were analyzed for p-AKT
expression by western blot analysis. Actin expression
was examined as an internal control to verify the
amounts of protein loading.
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Categorization of expression levels can significantly affect the
results of association assessments. Therefore, we also tested
another categorization of p-AKT and p-ERK1/2 expression into
two groups: low expression (no expression or weak expression),
and high expression (moderate or strong expression). Even using
that two-group categorization of expression, we observed a sig-
nificant association between p-AKT and p-ERK1/2 expression
(P = 0.018).
Effect of p-AKT expression on the survival of patients with endometrial 
cancer. We next examined the prognostic effect of p-AKT
expression. The mean follow-up time for all patients was
4.08 years for relapse-free survival (RFS; median, 3.51 years; range,
0.15–9.63 years) and 4.31 years for overall survival (OS; median,
3.75 years; range, 0.56–9.63 years). First, the effect of p-AKT
expression on RFS was analyzed. At the time of the last follow
up, 11 of the 63 patients (15.9%) had suffered relapses of endo-
metrial cancer. Figure 4 illustrates univariate outcomes based
on p-AKT expression. The RFS for the high- and low-expression
groups was 88.9 and 74.0%, respectively (P = 0.148), suggesting
that low p-AKT expression may be associated with lower RFS.
Next, the effect of p-AKT on OS was analyzed. At the time of
the last follow up, 12 of the 63 patients (20.6%) had died (eight




High (n = 36) Low (n = 27)
Age (years)
<60 (n = 39) 24 15
≥60 (n = 24) 12 12 0.3688
FIGO stage
I (n = 46) 26 20
II, III, IV (n = 17) 10 7 0.8698
Lymph-node metastasis
Negative (n = 58) 33 25
Positive (n = 5) 3 2 0.8930
Depth (myometrial invasion)
a, b (n = 47) 25 22
c (n = 16) 11 5 0.2774
Histopathological degree of differentiation
Grade 1 (n = 34) 21 13 0.5601
Grade 2, 3 (n = 29) 15 14
Menopause
Peri, pre (n = 23) 14 9 0.6504
Post (n = 40) 22 18
Body mass index
<25 (n = 38) 23 15 0.5035
≥25 (n = 25) 13 12
FIGO, International Federation of Gynecology and Obstetrics.
Table 3. Correlation between phosphorylated (p)-AKT expression and PTEN or PIK3CA status in endometrial cancer
p-AKT expression n
PTEN PIK3CA PTEN or PIK3CA
Mutation Wild type Mutation Wild type Mutation Wild type
Negative 10 4 6 2 8 6 4
Weak 8 3 5 1 7 3 5
Moderate 19 7 12 2 17 7 12
Strong 8 4 4 2 6 5 3
45 18 27 7 38 21 24
P-value 0.93 0.77 0.47
Table 4. Correlation between phosphorylated (p)-AKT and p-mTOR
expression in endometrial cancer
p-AKT expression n
p-mTOR expression
Negative Weak Moderate Strong
Negative 14 3 0 9 2
Weak 13 1 2 7 3
Moderate 27 1 3 18 5
Strong 9 0 2 5 2
Total 63 5 7 39 12
P = 0.54.
Table 5. Correlation between phosphorylated (p)-AKT and p-FOXO1/
03a expression in endometrial cancer
p-AKT expression n
p-FOXO1/3a expression
Negative Weak Moderate Strong
Negative 14 5 5 3 1
Weak 13 2 4 6 1
Moderate 27 4 5 13 5
Strong 9 1 2 5 1
Total 63 12 16 27 8
P = 0.60.
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from endometrial cancer, and four from other causes [breast cancer,
melanoma, liver cancer, and lung embolism]). There was little
difference in OS between the high- and low-p-ERK1/2-expression
groups (83.3 and 77.8%, respectively; P = 0.478).
Discussion
In the present study, we found that AKT is frequently activated
in endometrial cancer, based on the finding that approximately
60% of the patients expressed high levels of p-AKT. The first
notable finding in the present study is that PTEN mutation is not
significantly associated with p-AKT expression in endometrial
cancer, indicating that PTEN mutation does not necessarily lead
to activation of the PI3K–AKT pathway. This is in contrast to
a previous study by Kanamori et al., which found that PTEN
expression (evaluated by immunohistochemistry) was inversely
correlated with p-AKT expression in endometrial cancer.(23)
Ideally, inactivation of PTEN would be evaluated by examining
protein expression using immunohistochemistry or western blot
analysis, rather than by examining gene mutation. However, our
attempts at PTEN immunohistochemistry have produced non-
specific staining and unstable results, possibly due to a lack of
a reliable antibody (data not shown). In a recent study, Velasco
Fig. 3. Concordance of phosphorylated (p)-AKT
and p-ERK1/2 expression in endometrial cancer
specimens. Patient 9 showed negative staining
for p-AKT and p-ERK1/2, whereas both were
positive in patient 52. Staining for p-mTOR and
p-FOXO1/3a was positive in both patients. Note
the concordance of p-AKT and p-ERK1/2 expression
in each patient. (Original magnification ×200.
Scale bars = 50 μm.)




Negative Weak Moderate Strong
Negative 14 11 3 0 0
Weak 13 4 4 3 2
Moderate 27 4 11 7 5
Strong 9 3 0 5 1
Total 63 22 18 15 8
P = 0.0031.
Mori et al. Cancer Sci |  December 2007 | vol. 98 | no. 12 | 1887
© 2007 Japanese Cancer Association
et al. found no significant association between PTEN mutation
and the expression of p-AKT in endometrial cancer.(11) Similar
results have been reported for other tumor types. In a study of
more than 600 breast cancer patients, Panigrahi et al. found that
PTEN expression does not correlate with p-AKT expression.(24)
Osman et al. obtained similar results in a study of 204 prostate
cancer patients.(25) The present results are also consistent with
previous results of an in vitro analysis indicating that PTEN-
knockdown by short hairpin (sh)RNA in endometrial immortalized
cell lines does not effectively induce p-AKT expression.(19) These
findings support the theory that there are complex regulatory
pathways upstream of AKT other than PTEN mutation. One
candidate for such an upstream factor may be PIK3CA mutation,
which has been observed in a variety of cancers, including
colon,(26) breast,(27) stomach,(28) and ovary.(29) The PIK3CA gene,
mapped to 3q26, encodes the p110α catalytic subunit of PI3K,
and mutant p110α proteins have been shown to have enhanced
lipid-kinase activity compared to the wild-type protein, thereby
potentially activating the PI3K–AKT pathway and inducing
oncogenic transformation. Recent studies have identified PIK3CA
mutation in 20–40% of endometrial cancers.(10–12) The present
study identified PIK3CA mutations in 16% of endometrial
cancers. However, our study found no significant association
between PIK3CA mutation and p-AKT expression. We found
four cancers with both PTEN and PIK3CA mutations, but even
those cancers did not show enhanced p-AKT expression. This is
consistent with the study by Velasco et al. that failed to find an
association between PIK3CA mutation and p-AKT expression.(11)
These findings suggest that there might be additional factors
required for activating the PI3K–AKT pathway in endometrial
cancer, or either PTEN or p110α has additional functions
distinct from PI3K–AKT regulation.
Also in the present study, no correlation was observed
between p-AKT and downstream targets, including p-mTOR
and p-FOXO expression, indicating that AKT phosphorylation
does not necessarily lead to the activation of possible down-
stream targets, again suggesting that complex downstream
signaling pathways are involved in endometrial carcinogenesis.
The second notable finding in the present study is the strong
association between AKT and ERK1/2 activation in endometrial
cancer. This association may be due to several different molecular
events. First, there may be common factors upstream of AKT
and ERK1/2, such as epidermal growth factor receptor (EGFR)
and Her2. Obviously, a significant proportion of endometrial
cancers receive extracellular growth stimuli that initiate intracel-
lular signaling via receptor-type tyrosine kinases.(30,31) Eventually,
these common upstream signals induce expression of both AKT
and ERK. Simultaneous activation of AKT and ERK is therefore
not surprising. No data of a direct association between AKT and
ERK1/2 have been reported. Some relevant studies indicate that
AKT phosphorylates RAF1 directly, which is an upstream factor
of ERK, but this results in a decrease in RAF1 activity.(32) In one
study, ERK1/2 was coimmunoprecipitated with AKT in an
assembly of ERK1/2, AKT, RSK, and PDK1 in kidney tubular
cells, in which RSK acts as a bridge bringing ERK1/2 into prox-
imity with PDK1-associated AKT.(33) However, this association
also resulted in downregulation of AKT activity by ERK1/2.
Thus, there has been no reported evidence of a direct bio-
chemical association between AKT and ERK1/2 as coactivators.
Thus, it appears that common upstream factors or crosstalk
between signals is responsible for the simultaneous activation of
AKT and ERK1/2. One candidate mediator for crosstalk might
be KRAS mutation, which is known to activate PI3K directly or
indirectly.(22) However, we failed to find any correlation between
KRAS mutation and p-AKT expression, indicating that the story
is not so simple and complex regulatory pathways may exist for
the concomitant activation of AKT and ERK1/2 in endometrial
cancer. A recent study indicates that the RAF–MEK–ERK and
PI3K–PDK–AKT pathways cooperate to promote G0-G1-S-phase
cell-cycle progression in normal and cancer cells.(34) The present
data suggest that the proliferation of endometrial cancer cells is
maintained via such cooperative signaling pathways.
Finally, in the present study, we did not find an effect of p-AKT
expression on the prognosis of endometrial cancer. In univariate
analysis, higher p-AKT expression appeared to be associated
with better RFS, which is not consistent with the theory that
AKT has an antiapoptotic function. Whereas some previous
studies have observed a correlation between higher p-AKT
expression and poor clinical outcome in a variety of cancers,(35–38)
others have shown a correlation between lower p-AKT expres-
sion and poor clinical outcome.(23,39) Of particular interest is the
finding that higher AKT expression correlates with better prog-
nosis for tumors in estrogen-responsive tissues, including breast,
ovarian, and endometrial cancer tissue,(21,39) as was found in the
present study. In a recent study, we found that endometrial can-
cers with high ERK1/2 expression had better overall and RFS
than those with low expression;(18) the present results suggest a
similar relationship for AKT. How can we explain such a rela-
tionship between favorable prognosis and high ERK1/2 and
AKT expression? Although these physiologically important sig-
naling pathways are essential for the proliferation of normal and
cancer cells, disease progression in the late stage of endometrial
carcinogenesis probably requires other signaling pathways. For
Fig. 4. Kaplan–Meier plots of (a) relapse-free survival and (b) overall
survival of groups defined by phosphorylated (p)-AKT immunohistochemistry.
The tumors were divided into two groups (high and low expression
of p-AKT).
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example, during tumorigenesis in estrogen-dependent organs,
cancer cells are likely to lose expression of estrogen receptors
and achieve hormone-independent growth, leading to more
aggressive phenotypes in which genetic rearrangements such as
mutation, deletion, and translocation of genes make a greater
contribution to the malignant potential of cells. This theory
can be applied to p-AKT expression in endometrial cancer.
In summary, in the present study, AKT expression was observed
frequently in endometrial cancers in a PTEN-independent
manner, was strongly associated with ERK1/2 activation, and
was associated with relatively favorable prognosis. The present
study supports the presence of complex signaling pathways,
including the novel signaling cascades that might mask the con-
ventional tumorigenic PTEN–PI3K–AKT–mTOR pathway,
and suggests a close association between the ERK and PI3K
pathways in this tumor type.
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